The emerging literature on "nonpharmacological interventions" has not succeeded in providing long-term solutions for many people, such that expressions of need continue to recur on a regular basis.
Pain management for residents at the end-of-life, antipsychotic use in dementia residents and medication for epileptic residents were all hot issues tackled during the National Association of Directors of Nursing Administration in Long Term Care annual conference Monday.
It can almost be classified as a case of no good deed going unpunished. However, even though this is about long-term care, let's not be quite so skeptical. Progress is progress.
Elderly patients taking antipsychotics should be carefully monitored, especially after they first start taking the medication, due to a higher risk of hospitalization, a new study finds.
I'm an administrator who's read all of this stuff about overuse of antipsychotics on long-term care residents. I like and trust my director of nursing, medical director and clinical staff — to a degree, that is — but what can I do to REALLY know that we're not overusing this stuff, and would not be liable for some sort of adverse regulatory or court findings?
Pharmaceuticals giant Johnson & Johnson and some subsidiaries will pay more than $2.2 billion to settle claims that they inappropriately promoted antipsychotic drugs for use in nursing homes, the U.S. Department of Justice announced Monday. The agreement is one the largest ever of its kind, and will also settle charges that the companies paid kickbacks to the nation's largest long-term care pharmacy, Omnicare.
For decades, many providers have viewed antipsychotic drugs as a necessary evil for treating residents with dementia. But increasingly, these medications are just being seen as evil. So it's hardly a surprise that the government and the long-term care field are praising notable progress toward reducing their use by 15%.